We are live on ! Find out more
IOVA icon

Iovance Biotherapeutics
IOVA

269 hedge funds and large institutions have $6.9B invested in Iovance Biotherapeutics in 2020 Q4 according to their latest regulatory filings, with 57 funds opening new positions, 86 increasing their positions, 97 reducing their positions, and 39 closing their positions.

New
Increased
Maintained
Reduced
Closed

54% more call options, than puts

Call options by funds: $120M | Put options by funds: $77.8M

51% more capital invested

Capital invested by funds: $4.58B → $6.9B (+$2.32B)

46% more first-time investments, than exits

New positions opened: 57 | Existing positions closed: 39

22% more funds holding in top 10

Funds holding in top 10: 9 → 11 (+2)

7% more funds holding

Funds holding: 252 → 269 (+17)

5.83% more ownership

Funds ownership: 95.58% → 101.41% (+5.8%)

11% less repeat investments, than reductions

Existing positions increased: 86 | Existing positions reduced: 97

Holders
269
Holders Change
+17
Holders Change %
+6.75%
% of All Funds
4.76%
Holding in Top 10
11
Holding in Top 10 Change
+2
Holding in Top 10 Change %
+22.22%
% of All Funds
0.19%
New
57
Increased
86
Reduced
97
Closed
39
Calls
$120M
Puts
$77.8M
Net Calls
+$42M
Net Calls Change
+$15.8M

Top Buyers

1
AIM
ARK Investment Management
Florida
+$294M
2
Wellington Management Group
Wellington Management Group
Massachusetts
+$197M
3
CCM
Consonance Capital Management
New York
+$67.9M
4
Lord, Abbett & Co
Lord, Abbett & Co
New Jersey
+$53.1M
5
NAMA
Nikko Asset Management Americas
New York
+$35.9M

Top Sellers

1
GPP
Great Point Partners
Connecticut
-$117M
2
ACA
Avoro Capital Advisors
New York
-$80.8M
3
PA
Perceptive Advisors
New York
-$36.5M
4
Fidelity Investments
Fidelity Investments
Massachusetts
-$29.4M
5
Susquehanna International Group
Susquehanna International Group
Pennsylvania
-$27.1M
Name Holding Trade Value Shares
Change 		Change in
Stake
Neuberger Berman Group
101
Neuberger Berman Group
New York
$2.65M -$2.1M -53,000 -48%
Luther King Capital Management (LKCM)
102
Luther King Capital Management (LKCM)
Texas
$2.65M +$2.26M +57,030 New
ECM
103
Endurant Capital Management
California
$2.52M +$2.15M +54,221 New
SCM
104
Sio Capital Management
New York
$2.51M +$2.14M +54,000 New
Treasurer of the State of North Carolina
105
Treasurer of the State of North Carolina
North Carolina
$2.35M +$4.76K +120 +0.2%
MCM
106
Moore Capital Management
New York
$2.32M -$6.75M -169,982 -77%
SWP
107
Stratos Wealth Partners
Ohio
$2.3M +$329K +8,298 +20%
VOYA Investment Management
108
VOYA Investment Management
Georgia
$2.25M -$11.4M -286,239 -85%
Citigroup
109
Citigroup
New York
$2.24M +$304K +7,661 +19%
Thrivent Financial for Lutherans
110
Thrivent Financial for Lutherans
Minnesota
$2.19M – – –
ECM
111
ExodusPoint Capital Management
New York
$2.12M +$1.21M +30,495 +201%
Baird Financial Group
112
Baird Financial Group
Wisconsin
$1.94M +$342K +8,625 +26%
IP
113
Intellectus Partners
California
$1.93M +$272K +6,850 +20%
AAM
114
Advisors Asset Management
Colorado
$1.93M +$1.43M +36,130 +665%
KCM
115
Kennedy Capital Management
Missouri
$1.91M -$15.8K -397 -1%
Prudential Financial
116
Prudential Financial
New Jersey
$1.85M +$1.59M +39,945 New
AQR Capital Management
117
AQR Capital Management
Connecticut
$1.81M +$345K +8,689 +29%
Macquarie Group
118
Macquarie Group
Australia
$1.81M -$478K -12,046 -24%
Ensign Peak Advisors
119
Ensign Peak Advisors
Utah
$1.78M -$24.2K -610 -2%
WI
120
WBI Investments
New Jersey
$1.7M +$1.45M +36,566 New
Voloridge Investment Management
121
Voloridge Investment Management
Florida
$1.69M +$1.44M +36,311 New
AC
122
Athanor Capital
New York
$1.64M +$1.41M +35,416 New
TRCT
123
Tower Research Capital (TRC)
New York
$1.64M +$1.26M +31,705 +863%
DLPIC
124
Davide Leone & Partners Investment Company
United Kingdom
$1.61M +$1.38M +34,685 New
VIA
125
Vident Investment Advisory
Georgia
$1.53M -$357K -8,981 -21%
3 4
5
6 7

IOVA Hedge Fund Activity: Q4 2020 in Review

269 of the 5,651 institutional investors tracked by Wall St. Rank reported a position in Iovance Biotherapeutics (IOVA) for Q4 2020, worth a combined $6.9B — up 51% from $4.58B a quarter earlier.

Buyers outnumbered sellers: 57 funds opened new IOVA positions and 39 closed out — a net gain of 18 holders — while 86 added to existing stakes and 97 trimmed.

The largest buyer was ARK Investment Management, adding an estimated $294M. The largest seller was Great Point Partners, cutting an estimated $117M.

  • 269 institutional investors held Iovance Biotherapeutics (IOVA) as of Q4 2020, up from 252 in Q3 2020.
  • Funds reported $6.9B of Iovance Biotherapeutics stock for Q4 2020, up 51% quarter-over-quarter.
  • 57 funds opened new Iovance Biotherapeutics positions in Q4 2020 and 39 closed out, a net change of +18 holders.
  • The largest Iovance Biotherapeutics buyer in Q4 2020 was ARK Investment Management, an estimated $294M added.
  • The largest Iovance Biotherapeutics seller in Q4 2020 was Great Point Partners, an estimated $117M sold.

Based on aggregated 13F filings for Q4 2020.